Edition:
United Kingdom

Puma Biotechnology Inc (PBYI.OQ)

PBYI.OQ on NASDAQ Stock Exchange Global Select Market

64.20USD
26 Apr 2018
Change (% chg)

$0.95 (+1.50%)
Prev Close
$63.25
Open
$63.75
Day's High
$65.60
Day's Low
$63.45
Volume
127,958
Avg. Vol
256,008
52-wk High
$136.90
52-wk Low
$28.35

Chart for

About

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous))... (more)

Overall

Beta: 0.85
Market Cap(Mil.): $4,516.76
Shares Outstanding(Mil.): 37.21
Dividend: --
Yield (%): --

Financials

  PBYI.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -8.14 -- --
ROI: -224.57 1.58 14.38
ROE: -233.95 2.41 16.07

BRIEF-Puma Biotechnology And Pint Pharma Enter Licensing Agreement To Commercialize Nerlynx In Latin America

* PUMA BIOTECHNOLOGY AND PINT PHARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN LATIN AMERICA

03 Apr 2018

BRIEF-Puma Biotechnology ‍Nerlynx Included As Recommended Treatment Option In NCCN Clinical Practice Guidelines

* ‍NERLYNX INCLUDED AS RECOMMENDED TREATMENT OPTION IN NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY CENTRAL NERVOUS SYSTEM CANCERS

02 Apr 2018

BRIEF-Puma Biotechnology Requests EMA To Re-Examine the Negative Opinion Issued By CHMP For MAA For Neratinib

* PUMA BIOTECHNOLOGY SAYS ‍GIVEN WRITTEN NOTICE TO EMA TO REQUEST RE-EXAMINATION OF NEGATIVE OPINION ISSUED BY CHMP IN FEB 2018 FOR MAA FOR NERATINIB Source text for Eikon: (http://bit.ly/2G6kIc2) Further company coverage:

08 Mar 2018

BRIEF-Puma Biotechnology Inc Files For Non Timely 10-K - SEC Filing‍​

* PUMA BIOTECHNOLOGY INC FILES FOR NON TIMELY 10-K - SEC FILING‍​ Source text: (http://bit.ly/2F6s3qK) Further company coverage:

01 Mar 2018

BRIEF-Puma Biotechnology Q4 Loss Per Share $1.71

* PUMA BIOTECHNOLOGY REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

01 Mar 2018

EU panel recommends against nod for Puma Biotech's breast cancer drug

A European Medicines Agency (EMA) panel on Friday recommended against approving Puma Biotechnology's lead breast cancer drug, an outcome the U.S drugmaker had signalled last month.

23 Feb 2018

BRIEF-EMA Recommends Against Approval Of Puma Biotechnology's Breast Cancer Drug Neratinib‍​

* EU MEDICINES AGENCY RECOMMENDATIONS FOR FEBRUARY 2018 BREAST CANCER DRUG NERATINIB

23 Feb 2018

BRIEF-Puma Biotechnology And Canbridge Life Sciences Enter Into Exclusive Licensing Agreement To Commercialize Nerlynx In Greater China

* PUMA BIOTECHNOLOGY AND CANBRIDGE LIFE SCIENCES ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN GREATER CHINA Source text for Eikon: Further company coverage:

01 Feb 2018

BRIEF-Puma Biotechnology And Canbridge Life Sciences Enter Into Exclusive Licensing Agreement

* PUMA BIOTECHNOLOGY AND CANBRIDGE LIFE SCIENCES ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN GREATER CHINA

01 Feb 2018

BRIEF-Puma Biotechnology And Medison Pharma Enter Licensing Agreement To Commercialize Nerlynx In Israel

* PUMA BIOTECHNOLOGY AND MEDISON PHARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN ISRAEL

30 Jan 2018

Earnings vs. Estimates